SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline - August 3, 2018

NEW YORK, June 5, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MabVax Therapeutics Holdings ("MabVax" or the "Company") (NASDAQ: MBVX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired MabVax securities between March 14, 2016 and May 18, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/mbvx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) MabVax's internal controls over financial reporting were materially weak and deficient; (2) MabVax had incorrectly calculated and reported beneficial ownership of its shares, and permitted improper influence or control over the Company, and/or its officers and directors by certain shareholders; and, (3) consequently, MabVax's financial statements and Defendants' statements about MabVax's business, operations, and prospects, were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/mbvx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in MabVax you have until August 3, 2018 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-mabvax-therapeutics-holdings-mbvx--lead-plaintiff-deadline--august-3-2018-300660133.html

SOURCE Bronstein, Gewirtz & Grossman, LLC